Skip to content

Halozyme Therapeutics HALO Acquired in-process research and development

Acquired in-process research and development at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$228.9M+1.6%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$30M

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.

The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's acquired in-process research and development?
Halozyme Therapeutics (HALO) reported acquired in-process research and development of $71.22M in Q4 2025.
What does acquired in-process research and development mean?
Represents the cash outflow associated with acquiring research and development projects that have not yet reached technological feasibility. This is a critical indicator of a company's external innovation strategy and inorganic growth pipeline. It reflects the capital intensity of maintaining a competitive R&D portfolio in high-tech or life science sectors.